71 related articles for article (PubMed ID: 24098025)
1. Thymosin β4 was upregulated in recurred colorectal cancers.
Kang YJ; Jo JO; Ock MS; Chang HK; Lee SH; Ahn BK; Baek KW; Choi YH; Kim WJ; Leem SH; Cha HJ
J Clin Pathol; 2014 Feb; 67(2):188-90. PubMed ID: 24098025
[No Abstract] [Full Text] [Related]
2. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma.
Xi HQ; Zhao P
J Clin Pathol; 2011 Jun; 64(6):498-503. PubMed ID: 21415057
[TBL] [Abstract][Full Text] [Related]
3. Expression patterns of Thymosin β4 and cancer stem cell marker CD133 in ovarian cancers.
Ji YI; Lee BY; Kang YJ; Jo JO; Lee SH; Kim HY; Kim YO; Lee C; Koh SB; Kim A; Lee JY; Jung MH; Ock MS; Cha HJ
Pathol Oncol Res; 2013 Apr; 19(2):237-45. PubMed ID: 23055022
[TBL] [Abstract][Full Text] [Related]
4. CD44 is of functional importance for colorectal cancer stem cells.
Du L; Wang H; He L; Zhang J; Ni B; Wang X; Jin H; Cahuzac N; Mehrpour M; Lu Y; Chen Q
Clin Cancer Res; 2008 Nov; 14(21):6751-60. PubMed ID: 18980968
[TBL] [Abstract][Full Text] [Related]
5. AC133 expression associated with poor prognosis in stage II colorectal cancer.
Ying X; Wu J; Meng X; Zuo Y; Xia Q; Chen J; Feng Y; Liu R; Li L; Huang W
Med Oncol; 2013 Mar; 30(1):356. PubMed ID: 23322518
[TBL] [Abstract][Full Text] [Related]
6. CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer.
Horst D; Kriegl L; Engel J; Jung A; Kirchner T
Eur J Cancer; 2009 Jul; 45(11):2034-40. PubMed ID: 19403300
[TBL] [Abstract][Full Text] [Related]
7. Thymosin β4 expression in human tissues and in tumors using tissue microarrays.
Jo JO; Kang YJ; Ock MS; Kleinman HK; Chang HK; Cha HJ
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):160-7. PubMed ID: 20975530
[TBL] [Abstract][Full Text] [Related]
8. Cancer Stem Cell Markers Are Associated With Distant Hematogenous Liver Metastases But Not With Peritoneal Carcinomatosis in Colorectal Cancer.
Neumann J; Löhrs L; Albertsmeier M; Reu S; Guba M; Werner J; Kirchner T; Angele M
Cancer Invest; 2015; 33(8):354-60. PubMed ID: 26068177
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer.
Horst D; Kriegl L; Engel J; Kirchner T; Jung A
Cancer Invest; 2009 Oct; 27(8):844-50. PubMed ID: 19626493
[TBL] [Abstract][Full Text] [Related]
10. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients.
Artells R; Moreno I; Díaz T; Martínez F; Gel B; Navarro A; Ibeas R; Moreno J; Monzó M
Eur J Cancer; 2010 Feb; 46(3):642-9. PubMed ID: 20005089
[TBL] [Abstract][Full Text] [Related]
11. The stem cell marker CD133 is highly expressed in sessile serrated adenoma and its borderline variant compared with hyperplastic polyp.
Mohammadi M; Bzorek M; Bonde JH; Nielsen HJ; Holck S
J Clin Pathol; 2013 May; 66(5):403-8. PubMed ID: 23436931
[TBL] [Abstract][Full Text] [Related]
12. CD133 expression is correlated with poor prognosis in colorectal cancer.
Kashihara H; Shimada M; Kurita N; Iwata T; Sato H; Kozo Yoshikawa ; Higashijima J; Chikakiyo M; Nishi M; Matsumoto N
Hepatogastroenterology; 2014 Sep; 61(134):1563-7. PubMed ID: 25436343
[TBL] [Abstract][Full Text] [Related]
13. CD133 and ABCB5 as stem cell markers on sentinel lymph node from melanoma patients.
Gazzaniga P; Cigna E; Panasiti V; Devirgiliis V; Bottoni U; Vincenzi B; Nicolazzo C; Petracca A; Gradilone A
Eur J Surg Oncol; 2010 Dec; 36(12):1211-4. PubMed ID: 20573479
[No Abstract] [Full Text] [Related]
14. CD133 is a selective marker of CRC?
Del Rio P; Bonati E; Crafa P; Campanini N; Montana Montana C; Bezer L; Dell'Abate P; Sianesi M
Minerva Chir; 2013 Feb; 68(1):87-95. PubMed ID: 23584268
[TBL] [Abstract][Full Text] [Related]
15. Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer.
Nagata T; Sakakura C; Komiyama S; Miyashita A; Nishio M; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Ikoma H; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Kokuba Y; Sonoyama T; Otsuji E
Anticancer Res; 2011 Feb; 31(2):495-500. PubMed ID: 21378329
[TBL] [Abstract][Full Text] [Related]
16. Colorectal cancer stem cells--hype or real?: comment on "Combined CD133+/CD44+ expression as a prognostic indicator of disease-free survival in patients with colorectal cancer".
Ahuja N
Arch Surg; 2012 Jan; 147(1):24-5. PubMed ID: 22250107
[No Abstract] [Full Text] [Related]
17. Investigation of diagnostic utility and expression profiles of stem cell markers (CD133 and CD90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosis.
Yilmaz G; Akyol G; Cakir A; Ilhan M
Pathol Res Pract; 2014 Jul; 210(7):419-25. PubMed ID: 24702884
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy.
García VM; Batlle JF; Casado E; Burgos E; de Castro J; Belda C; Barriuso J; Sánchez JJ; García-Cabezas MÁ; González-Barón M; Cejas P
Colorectal Dis; 2011 Sep; 13(9):989-98. PubMed ID: 20718834
[TBL] [Abstract][Full Text] [Related]
20. Divergent expression of CD133 in different studies: the need for a consensus panel?
Sgambato A; Errico F; Caredda E; Puglisi MA; Cittadini A
Int J Cancer; 2011 May; 128(9):2247-9. PubMed ID: 20626045
[No Abstract] [Full Text] [Related]
[Next] [New Search]
